Journey Medical
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 58
- Market Cap
- $109.6M
- Introduction
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Drug Pipeline & Clinical Update - November 2024
Capital Rx's November 2024 Drug Update highlights new FDA approvals: Orlynvah™ for UTIs, Emrosi™ for rosacea, Danziten™ for Ph+ CML, and Revuforj™ for acute leukemia. Expanded indications include Abrysvo™, Jylamvo™, and Scemblix™. Generic Stendra™ launched. Costs and competition noted.
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Fortress Biotech announces FDA approval for Emrosi to treat rosacea and potential approval for cosibelimab for cutaneous squamous cell carcinoma, with financial results and recent corporate highlights for Q3 2024.
FDA Approves Emrosi for Rosacea in Adults
The FDA approved Emrosi (minocycline hydrochloride) for treating inflammatory rosacea in adults, based on positive phase 3 trial results showing superiority over current treatments and placebo, with no significant safety issues. Available in 2025, Journey Medical aims to establish Emrosi as a new standard of care.
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent ...
You need to enable JavaScript to run this app.
Emrosi Rosacea Treatment Receives FDA Approval
Journey Medical Corporation announced FDA approval of Emrosi, a treatment for rosacea's inflammatory lesions in adults, developed with Dr. Reddy’s Laboratories. Emrosi, showing superior efficacy in Phase 3 trials, aims to become the new standard of care, with U.S. availability expected by early 2025.
Journey Medical Corporation Reports Third Quarter 2024
Journey Medical Corporation announced FDA approval of Emrosi™ for rosacea treatment, expecting launch in Q1-Q2 2025, and reported $14.6 million in Q3 2024 revenues.
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
U.S. FDA approved Emrosi™ for rosacea treatment, with a launch expected in 2025. Journey Medical reported $14.6M in Q3 2024 revenues, a 4% decrease from 2023. The company focuses on dermatology products, with Emrosi seen as a potential best-in-class oral medication for rosacea.
FDA Roundup: Rosacea Treatment, Proposal to Remove Oral Phenylephrine from OTC Products
FDA approves Journey Medical’s Emrosi (minocycline hydrochloride extended-release capsules) for rosacea treatment, with initial supplies expected in Q1-Q2 2024. FDA also proposes removing oral phenylephrine from OTC nasal decongestants due to lack of efficacy, and mandates mail-back envelopes for opioid disposal under OA REMS program starting March 2025.
FDA approves Journey Medical’s rosacea treatment Emrosi
FDA approved Journey Medical’s Emrosi, a 40mg minocycline hydrochloride extended-release capsule, for rosacea treatment. Supported by Phase III trials, it aims to become a new standard of care. Journey plans US market availability by 2025, challenging Galderma’s dominance in rosacea treatments.
© Copyright 2025. All Rights Reserved by MedPath